Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Condition(s):Chronic Kidney Disease (CKD); Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease (CAD)Last Updated:December 2, 2021Recruiting
Hide Studies Not Open or Pending
Condition(s):Chronic Kidney Disease (CKD); Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease (CAD)Last Updated:December 2, 2021Recruiting
Condition(s):Bioequivalence, AUC, Cmax, PharmacokineticsLast Updated:June 22, 2016Completed
Condition(s):BioequivalenceLast Updated:March 2, 2022Completed
Condition(s):Platelet Aggregation; Adenosine; Coronary Artery Disease; Kidney Dysfunction; Antiplatelet TherapyLast Updated:April 24, 2020Completed
Condition(s):Metabolism of ClopidogrelLast Updated:February 23, 2022Completed
Condition(s):CLOPIDOGREL, POOR METABOLISM of (Disorder)Last Updated:April 11, 2014Unknown status
Condition(s):Acute Coronary SyndromeLast Updated:December 11, 2015Unknown status
Condition(s):Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel; Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of ClopidogrelLast Updated:June 19, 2012Completed
Condition(s):ClopidogrelLast Updated:May 30, 2017Completed
Condition(s):Cerebral Infarction; Clopidogrel,Poor Metabolism of (Disorder)Last Updated:June 16, 2015Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.